Abstracts tagged "Systemic sclerosis"

Abstract Number: 1704 • 2017 ACR/ARHP Annual Meeting
Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Tomonori Ishii¹, Yasushi Kawaguchi², osamu ishikawa³, naruhiko takasaawa⁴, takao kodera⁵, hidekata yasuoka⁶, yuichi takahashi⁷, osamu takai⁸, Izaya Nakaya⁹, Hiroshi Fujii¹⁰, Yukiko Kamogawa¹⁰, Yuko Shirota¹⁰, Tsuyoshi Shirai¹⁰, Yoko Fujita¹¹, shinichiro saito¹², Hiroaki Shimokawa¹³ and Hideo Harigae¹⁰, ¹Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Dermatology, Gunma University Graduate School of Medicine, gunma, Japan, ⁴Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sendai, Japan, ⁵Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ⁷Ｙｕ　Ｆａｍｉｌｙ　Ｃlinic, Sendai, Japan, ⁸Osaki Citizen Hospital, Sendai, Japan, ⁹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ¹⁰Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹¹Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹²IMS Meirikai Sendai General Hospital, Sendai, Japan, ¹³Department of Cardiovascular medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Patients with systemic sclerosis (SSc) often display Raynaud’s phenomenon, which causes digital skin ulcers. Since these ulcers are not associated with autoimmune factors, conventional…
Abstract Number: 1720 • 2017 ACR/ARHP Annual Meeting
TGF-ß-Induced Tissue Fibrosis in TBRIcaCol1Cre Transgenic Mice Is Abrogated By the Second Generation Tyrosine Kinase Inhibitor SKI-606 (Bosutinib)
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Bosutinib (SKI-606), a second-generation tyrosine kinase inhibitor that blocks the activity of the BCR-ABL kinase responsible for Philadelphia chromosome positive chronic myeloid leukemias, also…
Abstract Number: 2014 • 2016 ACR/ARHP Annual Meeting
A Deep Insight into Causes and Predictors of Death in Systemic Sclerosis
Muriel Elhai¹, Christophe Meune², Jerome Avouac¹, Fazia Amrouche³, Eric Hachulla⁴, Alexandra Balbir-Gurman⁵, Gabriela Riemekasten⁶, Paolo Airò⁷, Patricia E. Carreira⁸, Yannick Allanore⁹ and on behalf of EUSTAR co-authors, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris XIII University, Bobigny, France, ³Paris Descartes University, Cochin Hospital, Paris, France, ⁴CHU Lille, Lille, France, ⁵B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁶Department of Rheumatology, University of Luebeck, Lübeck, Germany, ⁷Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Immunogenetics, Cochin Institute, Paris, France
Background/Purpose : Systemic sclerosis (SSc), a connective tissue disease, is associated with high mortality rates. The main causes and risk factors for death are…
Abstract Number: 2893 • 2016 ACR/ARHP Annual Meeting
Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis
Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes², Luis Gonzalez Puig², Inmaculada Chalmeta Verdejo², Elena Grau Garcia^2,3, Carlos Feced Olmos², Eztizen Labrador Sanchez², Karla Arevalo Ruales², Rosa Negueroles Albuixech², Jorge Fragio Gil², Isabel Martinez Cordellat², Jose Luis Valero Sanz², Cristina Alcañiz Escandell^2,3, Carmen Najera Herranz², Gema Poveda Marin^2,3 and Jose Andres Roman², ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Santander, Spain, ²Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ³IIS La Fe, Valencia, Spain
Background/Purpose: In our study, over the half of the patients initially classified as Early-SSc progressed to SSc during follow-up. EUSTAR preliminary criteria were more frequent…
Abstract Number: 2897 • 2016 ACR/ARHP Annual Meeting
Microvascular Function in Systemic Sclerosis Patients with End-Stage Vascular Manifestations of the Disease
Tracy M. Frech¹, Phillip E. Gates², Daniel Machin³ and Anthony Donato⁴, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake, UT, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁴University of Utah and Salt lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Vasculopathy is a prominent feature of systemic sclerosis (SSc, scleroderma) and is involved in end-stage manifestations such as pulmonary arterial hypertension (PAH), digital ulcer…
Abstract Number: 2900 • 2016 ACR/ARHP Annual Meeting
The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey
Omer Nuri Pamuk¹, Mehmet Ali Balci², Salim Donmez³ and Gulsum Emel Pamuk⁴, ¹Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, ²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ³PsART study group, Ankara, Turkey, ⁴Hematology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, chronic, autoimmune disease. In this hospital based study, we aimed to evaluate the prevalence and incidence of SSc…
Abstract Number: 2901 • 2016 ACR/ARHP Annual Meeting
SSc and the Significance of Blood Group Antigens
Zsuzsanna Fabianne¹ and Annica Nordin², ¹Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden
Background/Purpose : Systemic sclerosis (SSc) is a rare disease, with a mean incidence 3.8 cases, prevalence 99 per million in Sweden. The two most important…
Abstract Number: 2903 • 2016 ACR/ARHP Annual Meeting
Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up
Alberto Sulli¹, Sabrina Paolino¹, Barbara Ruaro¹, Amelia Chiara Trombetta¹, Vanessa Smith², Maurizio Cutolo¹ and Carmen Pizzorni¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ²Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: Nailfold capillaroscopy is the validated technique to assess scleroderma microangiopathy, an early and dynamic event that may progress through different patterns of microvascular damage…
Abstract Number: 2915 • 2016 ACR/ARHP Annual Meeting
An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs
Yukie Yamaguchi¹, Yuichiro Shirai², Junya Ono^3,4, Yasushi Kawaguchi⁵, Kenji Izuhara³, Masataka Kuwana² and Michiko Aihara¹, ¹Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Biomolecular Sciences, Saga Medical School, Saga, Japan, ⁴Shino-Test Corporation, Sagamihara, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Periostin is one of the matricellular proteins, a class of ECM-related molecules defined by their ability to modulate cell–matrix interactions. Several lines of evidences…
Abstract Number: 818 • 2016 ACR/ARHP Annual Meeting
The Role of Endothelin 1 in Activation of Vascular Smooth Muscle Cells in Systemic Sclerosis; Increased Cell Proliferation and Resistance to Apoptosis Mediated By Endotehlin B Receptors
Shadia Nada¹, Yongqing Wang^1,2, Nezam Altorok¹ and Bashar Kahaleh¹, ¹Medicine/Rheumatology, University of Toledo, Toledo, OH, ²Medicine, University of Toledo, Toledo, OH
Background/Purpose: is overexpressed in SSc as illustrated by elevated circulating levels and increased tissue expression in involved organs. We previously reported vascular smooth muscle…
Abstract Number: 2917 • 2016 ACR/ARHP Annual Meeting
Nailfold Capillaroscopy and Mortality in Systemic Sclerosis
Thais Rohde Pavan, Rheumatology Service at the Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre – RS, Brazil., Rheumatology Service at the Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre – RS, Brazil., Porto Alegre, Brazil
Background/Purpose: To test the association of the severity of nailfold capillaroscopy (NFC) abnormalities with mortality in systemic sclerosis (SSc). Methods: One hundred and seventy SSc…
Abstract Number: 832 • 2016 ACR/ARHP Annual Meeting
Defining Skin Ulcers in Systemic Sclerosis: A Systematic Literature Review of Skin Ulcer Definitions and a Preliminary Consensus-Based New SSc Skin Ulcer Definition
Yossra A Suliman¹, Cosimo Bruni², Sindhu R. Johnson³, Emanuela Praino⁴, Mohamed Alemam⁵, Nabeel Borazan⁶, Laura Cometi⁷, Bethany Myers⁸, Dinesh Khanna⁹, Yannick Allanore¹⁰, Murray Baron¹¹, Thomas Krieg¹², Ariane L. Herrick¹³, Suzanne Kafaja¹⁴, Christopher Denton¹⁵, Marco Matucci Cerinic¹⁶ and Daniel E. Furst¹⁷, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁶Medicine, David Geffen School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, Department of Experimental and Clinical Medicine,, Florencei, Italy, ⁸UCLA Louise M. Darling Biomedical Library, Research Informationist, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Immunogenetics, Cochin Institute, Paris, France, ¹¹Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ¹²Universität zu Köln, Köln, Germany, ¹³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ¹⁴Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ¹⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹⁶Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ¹⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Skin ulcers in SSc are a major clinical challenge and there are various un-validated definitions of skin ulcers utilized in SSc-related clinical trials. We…
Abstract Number: 840 • 2016 ACR/ARHP Annual Meeting
Time Trends in Incidence and Mortality of Systemic Sclerosis in Denmark from 1995-2011: A Nationwide Cohort Study
Sheraz Butt¹, Charlotte Andersson², Søren Jacobsen³, Gunnar Gislason⁴ and Christian Torp-Pedersen⁵, ¹Department of Medicine, Glostrup Hospital, Glostrup, Denmark, ²Department of Medicine, Glostrup Hospital, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁴Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark, ⁵Aalborg University, Aalborg, Denmark
Time Trends In Incidence And Mortality Of Systemic Sclerosis In Denmark From 1995-2011: A Nationwide Cohort Study Background/Purpose: Epidemiological studies have documented an increasing incidence…
Abstract Number: 1849 • 2016 ACR/ARHP Annual Meeting
Fibroblast Growth Factor 9/ Fibroblast Growth Factor Receptor 3 Signaling Is Upstream of Several Profibrotic Pathways and Induces Fibroblast Activation and Tissue Fibrosis in SSc
Tatjana Mallano¹, Alfiya Distler¹, Clara Dees¹, Jingang Huang², Debomita Chakraborty³, Oliver Distler^4,5, Georg Schett⁶ and Joerg H.W Distler⁷, ¹Department of Internal Medicine III, Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ³Department of Internal Medicine III, Institute of Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ⁴Center of Exper Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, ⁶Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
FGF9 / FGFR3 signaling is upstream of several profibrotic pathways and induces fibroblast activation and tissue fibrosis in SSc Background/Purpose: Systemic sclerosis (SSc)…
Abstract Number: 1878 • 2016 ACR/ARHP Annual Meeting
Speckle Tracking Echocardiography: A Sensitive Technique for Detecting Early Left Ventricular Dysfunction in Patients with Systemic Sclerosis
Duygu Temiz Karadag¹, Tayfun Sahin², Senem Tekeoglu¹, Ozlem Ozdemir Işik¹, Ayten Yazici³, Fatma Ceyla Eraldemir⁴ and Ayse Cefle¹, ¹Rheumatology, Kocaeli University School of Medicine, Department of Rheumatology, Kocaeli, Turkey, ²Cardiology, Kocaeli University School of Medicine, Department of Cardiology, Kocaeli, Turkey, ³Umuttepe Yerleşkesi/IZMIT, Kocaeli University School of Medicine, Department of Rheumatology, Kocaeli, Turkey, ⁴Biochemistry, Kocaeli University School of Medicine, Department of Biochemistry, Kocaeli, Turkey
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by microvascular damage and excessive fibrosis in the skin and internal organs. Myocardial fibrosis which contributes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].